Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
Viking aims to enter the weight loss drug market.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.